SEC Letter to Allergan Hints at Additional non-GAAP Guidance

Details in a comment letter from the Securities and Exchange Commission to Allergan PLC may offer insight to the future of the regulator’s crackdown on company use of non-GAAP figures.

from WSJ.com: US Business http://ift.tt/2l7y5ku
via IFTTT